Your browser doesn't support javascript.
loading
Young Adult and Parent Willingness to Pay for Meningococcal Serogroup B Vaccination.
Huang, Liping; Srivastava, Amit; Fairchild, Angelyn; Whittington, Dale; Johnson, Reed.
Afiliación
  • Huang L; Patient Health and Impacts, Pfizer Inc, Collegeville, PA, USA.
  • Srivastava A; Orbital Therapeutics, Cambridge, MA, USA.
  • Fairchild A; Medical Development & Scientific Clinical Affairs, Pfizer Inc, Collegeville, PA, USA.
  • Whittington D; University of North Carolina at Chapel Hill, Kenan-Flagler Business School, Chapel Hill, NC, USA.
  • Johnson R; University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, NC, USA.
MDM Policy Pract ; 9(2): 23814683241264280, 2024.
Article en En | MEDLINE | ID: mdl-39139368
ABSTRACT
Introduction. Serogroup B (MenB) is the leading cause of invasive meningococcal disease among adolescents and young adults in the United States. The US Advisory Committee on Immunization Practices (ACIP) recommends MenB vaccination based on shared clinical decision making between patients and providers. However, suboptimal understanding of these recommendations could contribute to low vaccination awareness and coverage. Understanding young adult and parent expectations of their health care providers (HCPs) and the value they place on vaccine information could help inform a consistent approach to HCP MenB vaccination discussions and recommendations. Methods. Data collected via a discrete-choice experiment online survey were used to evaluate preferences and willingness to pay regarding MenB vaccination among US parents and young adults in 2019. Results. Of 2,388 respondents with valid data, 1,185 were parents of children aged 12 to 25 y, and 1,203 were young adults aged 18 to 25 y. Approximately 70% of parents and young adults indicated that they would react negatively if their HCP chose not to initiate a discussion with them about MenB vaccines. Neither parents nor young adults were willing to pay for additional time for MenB vaccine discussions with their HCP but were willing to pay an average of $416 and $282, respectively, for the vaccine. For parents and young adults, greater willingness to pay was associated with a provaccination attitude and the opinion that the HCP has a moral obligation to discuss the MenB vaccine with them. Conclusion. Both parents and young adults felt their HCP is responsible for initiating a discussion about MenB vaccination and disease risk and were willing to pay for the vaccine. These findings should help inform ACIP recommendations for meningococcal vaccination. Highlights ACIP recommends shared clinical decision making for MenB vaccination.Data were collected from young adults and parents of adolescents by online survey.We measured values and consultation preferences on MenB disease and vaccination.Young adults/parents strongly preferred doctor-initiated MenB vaccine discussion.Respondents were willing to pay for a MenB vaccine.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: MDM Policy Pract Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: MDM Policy Pract Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos